Testing IASO-782 for systemic lupus erythematosus
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new medicine called IASO-782 for people with systemic lupus erythematosus (SLE). It aims to see if the drug can help control lupus symptoms when added to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have a confirmed diagnosis of systemic lupus erythematosus (SLE)
- You are currently on standard lupus medications
- You are not pregnant and will use birth control during and after the trial
- You do not have active infections, recent heart problems, or a history of blood clots
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests IASO207, a new cell therapy designed to help people with severe lupus that hasn't improved with standard medications. The therapy works by modifying immune cells to reduce lupus activity.
This trial tests a new drug called IASO-782 for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) who haven't gotten better with standard treatments. The goal is to see if the drug can help control the immune system and improve blood counts.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
This study tests a new injectable drug, HC022, for people with lupus or cutaneous lupus. It aims to see if the drug is safe, tolerable, and begins to work.
This trial tests a new drug called 626 for people with systemic lupus erythematosus (SLE). It aims to see if the drug is safe and effective at reducing disease activity.
Hear when a new SLE - Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.